The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Patients Suffering from Different Clinical Variants of Psoriasis
- PMID: 36233422
- PMCID: PMC9572740
- DOI: 10.3390/jcm11195553
The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Patients Suffering from Different Clinical Variants of Psoriasis
Abstract
Background: Quality of life (QoL) and sleep, which are essential for well-being in the mental, physical, and socioeconomic domains, are impaired in psoriatic patients. However, the exact role of the clinical subtype of psoriasis in this aspect remains poorly studied.
Objectives: The aim of this study was to investigate differences in QoL impairment and sleeping problems in patients suffering from various clinical subtypes of psoriasis and to evaluate the effects of pruritus on QoL.
Methods: This cross-sectional, multicenter study included 295 eligible subjects with diagnosed psoriasis. Each patient was examined with the use of the same questionnaire. Measures included predominant subtype of psoriasis, disease severity, pruritus scores, patients' health-related QoL and the incidence of sleep disturbance.
Results: The QoL of most patients was decreased irrespectively of clinical psoriasis subtype, however, the most impaired QoL was in patients with erythrodermic psoriasis. The majority of patients reported sleep disturbances caused by pruritus, albeit there was no relevant differences between analyzed subgroups in this aspect of patients' well-being. Pruritus was an important factor determining QoL and sleeping problems in the studied population.
Conclusions: Identifying the most disturbing area of life and recognizing the most bothersome subjective symptoms of psoriasis are pivotal to focusing on the most relevant treatment goal and achieving therapeutic success.
Keywords: itch; itching; palmoplantar pustulosis; pruritus; psoriasis; quality of life; quality of sleep; sleep disorders; sleep disturbances.
Conflict of interest statement
K.J. has been a subinvestigator in clinical trials sponsored by Arcutis, Corbus, Kymab Limited, Novartis, Galderma, and Pfizer. A.R. has been a consultant or speaker for AbbVie, Bioderma, Bristol-Myers Squibb, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, and Trevi; and principal investigator or subinvestigator in clinical trials sponsored by AbbVie, Arcutis, Argenx, Corbus, Drug Delivery Solutions Ltd., Eli Lilly, Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Trevi, and VielaBio.
Figures


Similar articles
-
Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study.Sci Rep. 2023 Oct 16;13(1):17541. doi: 10.1038/s41598-023-44757-5. Sci Rep. 2023. PMID: 37845323 Free PMC article.
-
Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study.Life (Basel). 2021 Jun 27;11(7):623. doi: 10.3390/life11070623. Life (Basel). 2021. PMID: 34199131 Free PMC article.
-
Pruritus and sleep disturbances in patients with psoriasis.Arch Dermatol Res. 2020 Mar;312(2):103-111. doi: 10.1007/s00403-019-01998-7. Epub 2019 Oct 15. Arch Dermatol Res. 2020. PMID: 31616971
-
Interplay of Itch and Psyche in Psoriasis: An Update.Acta Derm Venereol. 2016 Aug 23;96(217):55-7. doi: 10.2340/00015555-2374. Acta Derm Venereol. 2016. PMID: 27282194 Review.
-
Molecular Aspects of Pruritus Pathogenesis in Psoriasis.Int J Mol Sci. 2021 Jan 16;22(2):858. doi: 10.3390/ijms22020858. Int J Mol Sci. 2021. PMID: 33467067 Free PMC article. Review.
Cited by
-
Skin-Related Sexual Life Questionnaire (SRSLQ): Creation and Validation of the Questionnaire.Medicina (Kaunas). 2023 Nov 17;59(11):2023. doi: 10.3390/medicina59112023. Medicina (Kaunas). 2023. PMID: 38004072 Free PMC article.
-
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248. doi: 10.1007/s13555-024-01224-x. Epub 2024 Jul 30. Dermatol Ther (Heidelb). 2024. PMID: 39080153 Free PMC article.
-
Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study.Sci Rep. 2023 Oct 16;13(1):17541. doi: 10.1038/s41598-023-44757-5. Sci Rep. 2023. PMID: 37845323 Free PMC article.
-
Pruritus in Palliative Care: A Narrative Review of Essential Oil-Based Strategies to Alleviate Cutaneous Discomfort.Diseases. 2025 Jul 23;13(8):232. doi: 10.3390/diseases13080232. Diseases. 2025. PMID: 40863207 Free PMC article. Review.
-
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.Dermatol Ther (Heidelb). 2025 Aug 11. doi: 10.1007/s13555-025-01509-9. Online ahead of print. Dermatol Ther (Heidelb). 2025. PMID: 40788331
References
LinkOut - more resources
Full Text Sources
Research Materials